Sumitomo Mitsui Trust Group
MRTX

Sumitomo Mitsui Trust Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,442
Closed -$572K – 1161
2020
Q3 		$572K Sell
3,442
-2,120
-38% -$290K ﹤0.01% 1024
2020
Q2 		$635K Buy
5,562
+160
+3% +$15.5K ﹤0.01% 1006
2020
Q1 		$415K Buy
+5,402
New +$484K ﹤0.01% 1015

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sumitomo Mitsui Trust Group's MRTX Position: Q4 2020 in Review

Sumitomo Mitsui Trust Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2020, closing a stake of 3,442 shares — an estimated $572K sold.

Sumitomo Mitsui Trust Group first reported a position in MRTX in Q1 2020 and held it in 3 quarters. The position peaked at $635K in Q2 2020. 284 funds tracked by Wall St. Rank hold MRTX as of Q4 2020.

  • Sumitomo Mitsui Trust Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 3,442 Mirati Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $572K.
  • Sumitomo Mitsui Trust Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 3 quarters.
  • Sumitomo Mitsui Trust Group's Mirati Therapeutics, Inc. Common Stock position peaked at $635K in Q2 2020.
  • 284 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q4 2020, filed 5 Feb 2021.